SCM
CRBU icon

Sterling Capital Management’s Caribou Biosciences CRBU Stock Holding History

Sterling Capital Management’s Portfolio CRBU Stock Details CRBU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-1,478
Closed -$1.35K – 3292
2025
Q1 		$1.35K Sell
1,478
-1,316
-47% -$1.71K ﹤0.01% 2717
2024
Q4 		$4.44K Buy
2,794
+2,539
+996% +$5.11K ﹤0.01% 2518
2024
Q3 		$500 Buy
+255
New +$522 ﹤0.01% 2868

Other funds holding CRBU

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sterling Capital Management's CRBU Position: Q2 2025 in Review

Sterling Capital Management sold out of Caribou Biosciences (CRBU) in Q2 2025, closing a stake of 1,478 shares — an estimated $1.35K sold.

Sterling Capital Management first reported a position in CRBU in Q3 2024 and held it in 3 quarters. The position peaked at $4.44K in Q4 2024. 129 funds tracked by Wall St. Rank hold CRBU as of Q2 2025.

  • Sterling Capital Management reported no remaining Caribou Biosciences position as of Q2 2025 after selling out during the quarter.
  • Sterling Capital Management sold 1,478 Caribou Biosciences shares in Q2 2025, an estimated $1.35K.
  • Sterling Capital Management first reported a position in Caribou Biosciences in Q3 2024 and held it in 3 quarters.
  • Sterling Capital Management's Caribou Biosciences position peaked at $4.44K in Q4 2024.
  • 129 funds tracked by Wall St. Rank held Caribou Biosciences as of Q2 2025.

Based on Sterling Capital Management's 13F filing for Q2 2025, filed 6 Aug 2025.